摘要
目的探讨健脾益肾方加减对早中期糖尿病肾病(Diabetic nephropathy,DN)患者疗效及血清转化生长因子-β1(Transforming growth factor-β1,TGF-β1)、胰岛素样生长因子-1(Insulin-like growth factor 1,IGF-1)、血管内皮生长因子(Vascular endothelial growth factor,VEGF)的影响。方法选取2019年6月—2021年6月河南省周口市中医院收治的DN患者90例,采用随机数字表法分为对照组和治疗组,每组各45例。对照组采用常规西医治疗,治疗组在对照组的基础上采用健脾益肾方加减治疗。治疗3个月后,观察比较两组患者临床疗效、不良反应发生率,治疗前后血清TGF-β1、IGF-1、VEGF水平,中医证候积分、肾功能指标[尿白蛋白排泄率(Urinary albumin excretion rates,UAER)、血尿素氮(Blood urea nitrogen,BUN)、血清肌酐(Serum creatinine,SCr)、内生肌酐清除率(Endogenous creatinine clearance,CCr)]水平。结果治疗后治疗组临床总有效率84.44%(38/45)与对照组64.44%(29/45)比较,差异有统计学意义(P<0.05)。治疗后两组患者中医证候积分均较治疗前降低,差异有统计学意义(P<0.05);且治疗组中医证候积分较对照组降低,差异有统计学意义(P<0.05)。治疗后两组患者UAER、BUN水平均较治疗前降低,SCr、CCr水平均较治疗前升高,差异有统计学意义(P<0.05);且治疗组UAER、BUN水平均较对照组降低,SCr、CCr水平均较对照组升高,差异有统计学意义(P<0.05)。治疗后两组患者血清TGF-β1、IGF-1、VEGF水平均较治疗前降低,差异有统计学意义(P<0.05);且治疗组血清TGF-β1、IGF-1、VEGF水平均较对照组降低,差异有统计学意义(P<0.05)。治疗期间,两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论健脾益肾方加减对DN的治疗具有积极作用,能明显改善患者临床症状,控制DN患者血糖,保护肾功能,降低血清TGF-β1、IGF-1、VEGF水平。
Objective To investigate the effect of the modified Jianpi Yishen Prescription on early and middle-stage diabetic nephropathy(DN)and its influence on serum transforming growth factorβ1(TGF-β1),insulin-like growth factor-1(IGF-1),and vascular endothelial growth factor(VEGF).Methods Ninety DN patients admitted to the Zhoukou Hospital of Traditional Chinese Medicine(TCM)from June 2019 to June 2021 were included and divided into a control group and an observation group by the random number table,with 45 cases in each group.The control group was treated with conventional western medicine,and the observation group was treated with the modified Jianpi Yishen Prescription based on the treatment of the control group.After three months of treatment,the clinical efficacy and incidence of adverse reactions of the two groups were observed and compared.The levels of serum TGF-β1,IGF-1,and VEGF,the TCM syndrome scores,and renal function indexes[urine albumin excretion rate(UAER),blood urea nitrogen(BUN),serum creatinine(SCr),and endogenous creatinine clearance rate(CCr)]before and after treatment of the two groups were compared.Results The total effective rate of the observation group[84.44%(38/45)]was significantly higher than that of the control group[64.44%(29/45)](P<0.05).After treatment,the TCM syndrome scores in the two groups were significantly lower than those before treatment(P<0.05),and the TCM syndrome score in the observation group was lower than that in the control group(P<0.05).After treatment,the levels of UAER and BUN in the two groups were lower and the levels of SCr and CCr were higher as compared with the control group(P<0.05).As compared with the control group,the levels of UAER and BUN in the observation group were decreased,and the levels of SCr and CCr were increased(P<0.05).After treatment,the levels of serum TGF-β1,IGF-1,and VEGF were lower than those before treatment(P<0.05).As compared with the control group,the levels of serum TGF-β1,IGF-1,and VEGF were decreased(P<0.05).The comparison of the in
作者
张英杰
王秉新
朱剑南
闫爱华
刘秋艳
ZHANG Ying-jie;WANG Bing-xin;ZHU Jian-nan;YAN Ai-hua;LIU Qiu-yan(Department of Diabetic Nephrology,Zhoukou Hospital of Traditional Chinese Medicine,Zhoukou Henan 466000)
出处
《世界中西医结合杂志》
2023年第1期118-122,共5页
World Journal of Integrated Traditional and Western Medicine
基金
河南省中医药科学研究专项课题(2018ZY3060)。
关键词
健脾益肾方
糖尿病肾病
转化生长因子-Β1
胰岛素样生长因子-1
血管内皮生长因子
Jianpi Yishen Prescription
Diabetic Nephropathy
Transformation Growth Factor-β1
Insulin-like Growth Factor-1
Vascular Endothelial Growth Factor
